Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome

Haematologica

Volumn 96, Issue 3, 2011, Pages 441-449

  della Porta, Matteo G ^a   Malcovati, Luca ^a   Strupp, Corinna ^b   Ambaglio, Ilaria ^a   Kuendgen, Andrea ^b   Zipperer, Esther ^b   Travaglino, Erica ^a   Invernizzi, Rosangela ^a   Pascutto, Cristiana ^a   Lazzarino, Mario ^a   Germing, Ulrich ^b   Cazzola, Mario ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Comorbidity; Myelodysplastic syndrome; Risk stratification

Indexed keywords

ADULT; AGED; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; GERMANY; HEALTH STATUS; HEART DISEASE; HUMAN; ITALY; KIDNEY DISEASE; LIFE EXPECTANCY; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELODYSPLATIC SYNDROME SPECIFIC COMORBIDITY INDEX; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROGNOSTIC SCORING SYSTEM; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SOLID TUMOR; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; COMORBIDITY; FEMALE; GERMANY; HEART DISEASES; HUMANS; ITALY; KIDNEY DISEASES; LIVER DISEASES; LUNG DISEASES; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 79952346792     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.033506     Document Type: Review

References (40)

1. Cazzola M, Malcovati L. Myelodysplastic syndromes--coping with ineffective hematopoiesis. N Engl J Med. 2005;352(6): 536-8.
2. Germing U, Strupp C, Kundgen A, Bowen D, Aul C, Haas R, et al. No increase in agespecific incidence of myelodysplastic syndromes. Haematologica. 2004;89(8):905-10.
3. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45-52.
4. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361(19): 1872-85.
5. Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States medicare beneficiaries. J Clin Oncol. 2010;2010 Apr 26. [Epub ahead of print].
6. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC, 2008.
7. Malcovati L, Della Porta M, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria. A basis for clinical decision-making. J Clin Oncol. 2005; 23:7594-603.
8. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-95.
9. Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27(5):754-62.
10. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-88.
11. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-10.
12. Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol. 2008;83(10):765-70.
13. Cazzola M, Malcovati L. Prognostic classification and risk assessment in myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010;24(2):459-68.
14. Kuendgen A, Strupp C, Aivado M, Hildebrandt B, Haas R, Gattermann N, et al. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol. 2006; 24(34):5358-65.
15. Alessandrino EP, Della Porta MG, Bacigalupo A, Van Lint MT, Falda M, Onida F, et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood. 2008;112(3):895-902.
16. Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Vercelli M, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20(2):494-502.
17. Zipperer E, Pelz D, Nachtkamp K, Kuendgen A, Strupp C, Gattermann N, et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica. 2009;94(5):729-32.
18. Della Porta MG, Malcovati L. Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. Haematologica. 2009;94(5):602-6.
19. Sperr WR, Wimazal F, Kundi M, Baumgartner C, Nosslinger T, Makrai A, et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCTCI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol. 2010;21(1):114-9.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
21. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-9.
22. Sorror ML, Giralt S, Sandmaier BM, De Lima M, Shahjahan M, Maloney DG, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110(13):4606-13.
23. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25 (27):4246-54.
24. Geraci JM, Escalante CP, Freeman JL, Goodwin JS. Comorbid disease and cancer: the need for more relevant conceptual models in health services research. J Clin Oncol. 2005;23(30):7399-404.
25. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-99.
26. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-302.
27. Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Bauman I, et al. Myelodysplastic syndromes/Neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., eds. WHO classification of tumours of hamatopoietic and lymphoid tissues. Lyon: IARC, 2008:88-93.
28. Vardiman JW, Brunning RD, Arber DA, Le Beau MM, Porwit A, Tefferi A, et al. Introduction and overview of the classification of the myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC, 2008:18-30.
29. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control. 1974;19(6):716-23.
30. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 2008;26 (24):3913-5.
31. Alessandrino EP, Della Porta MG, Bacigalupo A, Malcovati L, Angelucci E, Van Lint MT, et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica. 2010;95 (3):476-84.
32. de Witte T, Hagemeijer A, Suciu S, Belhabri A, Delforge M, Kobbe G, et al. Value of allogeneic stem cell transplantation versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: a prospective randomized European intergroup trial. Haematologica. 2010;95(10):1754-61.
33. Kroger N, Zabelina T, van Biezen A, Brand R, Niederwieser D, Martino R, et al. Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. 2011;96(2):291-7.
34. Ambaglio I, Travaglino E, Della Porta MG, Pascutto C, Ubezio M, Invernizzi R, et al. The impact of the degree of anemia on survival of patients with myelodysplastic syndrome. A basis for prognostic assessment and clinical decision making [abstract]. Haematologica. 2010;95(6 Suppl 2):124-5.
35. Jadersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, et al. Erythropoietin and granulocytecolony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26(21):3607-13.
36. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008;111(2):574-82.
37. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for lowrisk myelodysplasia is associated with improved outcome. Blood. 2004;104(2): 579-85.
38. Deschler B, de Witte T, Mertelsmann R, Lubbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica. 2006;91(11):1513-22.
39. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061-7.
40. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. Jama. 2004;291(22):2720-6.